ALPCO received 510(k) clearance from the US FDA for its new fecal Calprotectin Chemiluminescence ELISA test. The ALPCO Calprotectin Chemiluminescence ELISA’s superior clinical accuracy will enable clinical laboratories to provide the most accurate results to gastroenterologists facing the challenges of differentiating IBD from IBS.
Salem, NH, October 30, 2019 –(PR.com)– ALPCO, a leading developer and manufacturer of life science test solutions to advance research and improve clinical outcomes, announced today that the US Food and Drug Administration (FDA) granted its Calprotectin Chemiluminescence ELISA 510(k) clearance. The ALPCO Calprotectin Chemiluminescence ELISA, the latest addition to ALPCO’s STELLUX® product portfolio, has the highest clinical specificity of any FDA cleared calprotectin test. This feature will enable clinical laboratories to provide the most accurate results to gastroenterologists facing the challenge of differentiating inflammatory bowel disease (IBD) from irritable bowel syndrome (IBS).